Jonas Karl Olaf Brambeck

Quiatech AB develops and manufactures drugs. It is a research based company that develops enabling technologies for genetic analysis, molecular diagnostics, and gene-based therapeutics in the expanding market of DNA technologies that offer significant improvements in the quality of DNA microarray and other DNA oligonucleotide data. It has also developed a new modified RNA chemistry (Qt RNA Technology) utilizing a novel 2 protecting group on the RNA amidites, this development greatly improves the synthesis conditions, producing fully functional RNA at high yields. It is headquartered in Uppsala, Sweden.

Nuevolution AB engages in pharmaceutical and biotechnology discovery. Its activities include research and development, and licensing drugs and treatment of oncology and chronic inflammatory diseases including cancer. It offers the platform Chemetics, which enables discovery of small molecule drug candidates for specific indications addressing target diseases. The company was founded by Henrik Pedersen, Alex Haahr Gouliaev, and Mads Nørregaard-Madsen in May 2001 and is headquartered in Copenhagen, Denmark.

OLIGOvation AB develops enabling technologies for genetic analysis, molecular diagnostics and gene-based therapeutics. It offers services in the market of DNA technologies that offer improvements in the quality of DNA microarray and other DNA oligonucleotide data. The company was founded in February, 2000 and is headquartered in Uppsala, Sweden.

Airsonett AB is a holding company that is engaged in the research and development of a non-pharmaceutical treatment for asthma. Its product Airsonett is based on temperature controlled Laminar Airflow technology that creates a radically reduced allergen exposure in the breathing zone for treatment of asthma, allergic rhinitis, and atopic eczema. The company was founded by Jan Tommy Lennart Hedberg, Jan Kristensson, and Dan Kristensson in 2000 and is headquartered in Ängelholm, Sweden.

Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden.

RSPR Pharma AB develops therapeutics for inflammatory vascular diseases. The firm's products are used to treat diseases such as atherosclerosis and abdominal aortic aneurysm. The company was founded by Carl-Johan Dalsgaard in 2006 and is headquartered in Stockholm, Sweden.

Avidicare AB operates as a medical device company. It specializes in the management of airborne bacteria and virus pollution at hospitals. The firm provides Opragon, a ventilation system for reduction of airborne bacterial contamination in various hospital environments primarily for infection sensitive surgery. The company offers Opragon for preparation rooms, operating theaters, and hybrid rooms; and air curtains and external air showers. Avidicare was founded in 2010 and is headquartered in Lund, Sweden.

Gesynta Pharma AB develops and manufactures novel oral treatments for patients with chronic inflammatory conditions. The company was founded by Gunilla Anders Ekström, Charlotte Elisabet Edenius, Urban Paulsson, Ralf Morgenstern, Per-Johan Göte Jakobsson and Patric Stenberg in 2017 and is headquartered in Solna, Sweden.